Here are your MiTeGen Hottest Tweets in SBDD with DARPin scaffolds stealing the show cracking tough...
MiTeGen Hottest Tweets in SBDD (11/23)
This month's your MiTeGen Hottest Tweets in SBDD come with highlights across all topics including significant buzz around the latest software updates in RELION and CryoSPARC:
Are you attending the #PSDI2023 meeting https://t.co/9ZEG4tNDSF in Cambridge? Then stop by our MiTeGen table and see tools & instruments for structural biology research, whether it's #cryoem or #crystallography - Stop and talk with Rachel and Joyce to learn more pic.twitter.com/CaYDbxOLXA
— MiTeGen (@MiTeGen) November 13, 2023
Tough drug targets
Nature research paper: Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2 https://t.co/l6K7oK3QwD
— nature (@Nature) November 3, 2023
Structure of human TRPM8 channel | Commun Biolhttps://t.co/jERrjD9EKo #CryoEM #TRPchannel #MembraneProteins pic.twitter.com/msGZu3jrPA
— Membrane Protein PDB (@MemProtPDB) October 19, 2023
First time polyamine is visualized in the pore of ionotropic glutamate receptor (iGluR). Structures of AMPA receptor complexes with auxiliary subunits y5 and CNIH2. Collaboration with A. Korman and D. Jones (NYU). @shantigangwar @LauraYen42 @MariaKarela3https://t.co/TT7NaUOBcQ pic.twitter.com/9PBq3wRUZT
— Alexander Sobolevsky (@AlexanderSobol6) October 18, 2023
Thrilled to present our manuscript out today in @CellCellPress. A tour-de-force on anaphylatoxin complement receptors - 9 (!!!) unique GPCR structures: C3aR/C5aR1, biased/partial/full agonist, Go/Gq, mouse/human. https://t.co/YDxiqKQTQd pic.twitter.com/tjzsOuM1GD
— Cornelius Gati (@CorneliusGati) October 17, 2023
1/3 Today I can proudly present the first preprint from my project group @mpimoph!https://t.co/dl8gRNFRYE
— Tobias Raisch (@TobiasRaisch) November 4, 2023
We determined the #CryoEM structure of the Slo1 potassium channel in complex with the regulatory subunit γ1 and propose a mechanism of how γ1 can activate Slo1. pic.twitter.com/tPan6JCOc4
new release1
— Hideaki E. Kato (@emeKato) November 9, 2023
SpSLC9C1 in lipid nanodiscs
apo
8PCZ: dimer
8PD2,3,5,7: protomer state 1-4
w/ cAMP
8PD8: dimer
8PD9: protomer state 1
w/ cGMP
8PDU: dimer
8PDV: protomer
"Structures of a sperm-specific solute carrier gated by voltage and cAMP"
Paulino lab. Nature. pic.twitter.com/gV3TYCbaLq
Nice!
— BryanRoth (@zenbrainest) October 20, 2023
H4 Receptor structureshttps://t.co/iFaLEplyXb
The weird and wonderful
We're continuing to share the fantastic photos from this year's #LMBImageCompeition every Friday.
— MRC Laboratory of Molecular Biology (@MRC_LMB) November 24, 2023
Next up is this runners-up entry of a tomogram of catalase nanocrystals. pic.twitter.com/LqhPhJauy4
Sample preparation
Here is the relative ice thickness comparison between our MBP and membrane protein data sets (from cryoSPARC). https://t.co/nyIDPpZcFz pic.twitter.com/zRGBSqGpxX
— Han Kim (@Kim_Hanseong) November 21, 2023
Attention #cryoem Practitioners - A new grid storage box is available featuring easy to see high contrast colors - Works with clipped & unclipped girds - Has unique & enlarged grid chambers - Rotatable transparent protective lid - Learn more https://t.co/Hw6Fqf1Ied pic.twitter.com/c2rgF2AMzO
— MiTeGen (@MiTeGen) October 10, 2023
Found this in my colleague's notes for clipping cryo-EM grids.
— Meryl Haas (@MerylHaas) October 23, 2023
DON'T BREATHE
EVER!
😂 pic.twitter.com/woSGfuT9XL
Take the frustration out of clipping your #cryoem grids - Try the new line of grid clipping tools - These tools make loading of c-clips and clip grids easier and helps you avoid frost from environmental moisture - Learn More https://t.co/TT4t61Oepb pic.twitter.com/4tMZZgLURS
— MiTeGen (@MiTeGen) November 8, 2023
Better imaging
Starting with EPU 3.6 the image shift data will be indeed in the file names between the beam tilt id 🎉(photo from EPU 3.6 release notes) https://t.co/HDNKr1AQDW https://t.co/w9z5AIkJVD pic.twitter.com/cf5urjACg9
— Dustin Reed Morado (@DustinMorado) November 7, 2023
So #cryoEM community - do you use an objective aperture when collecting your data? Especially in microscopes with an EF. I know that it depends on the sample but do you see any benefits in data processing when inserted? 🔬 ❄️
— Dominik Hrebik (@F4ustus) October 19, 2023
Processing and IT
I was talking about using 3D Zernike polynomials to "normalise" results from flexibility analyses - code is available and I'm happy to chat about the concept further :) here's a cool movie showing a GPCR reconstruction using a sum of Zernike polynomials to order 150. https://t.co/OakFNueDxk pic.twitter.com/gbQom5MmSZ
— Charles Bayly-Jones (@bj_charles) November 25, 2023
I'm not sure if outputs from 3DVA or Mulltibody are suitable for atomic model refinement. These maps are generated with very crude approximations and show many artifacts. There are no half map pairs for validation. https://t.co/XkcpxtPiWb
— とりさん (@biochem_fan) November 9, 2023
1/ #CryoSPARC v4.4 is here! 🚀
— Structura Biotechnology (@structurabio) November 8, 2023
Updates include tools to streamline repeat #cryoEM processing, reference based motion correction, orientation diagnostics, symmetry tools, improved 3DFlex, caching, data cleanup and more!https://t.co/M3mLGtFPIq pic.twitter.com/tWl9WzfAlA
Once again @bradyajohnston brings a gun to a knife fight. Holograms on his poster 😯 ... that's cheating 😅 #PPG2023 pic.twitter.com/HTjh9iiSBP
— Perth Protein Group (@PerthProteins) November 4, 2023
Interesting status update from DeepMind on AlphaFold (just that, no model, paper, or code). All atom version in the works (similar to RFAA). Meaningful gains on small molecules but far from 'solved' (think AF1 vs AF2). Same w/nucleic acids and antibodies. https://t.co/2hEowQ4gxN pic.twitter.com/nVetmAXfnV
— Mohammed AlQuraishi (@MoAlQuraishi) October 31, 2023
Super excited to present #Blush and with it expand the applicability of cryo-EM. We reconstruct one of the smallest complexes ever with cryo-EM. A 40 kDa protein-RNA complex. https://t.co/uaNn6RjVdX
— Dari Kimanius (@kimanius) October 24, 2023
But how do we make sure we're not overfitting?
🧵1/4 pic.twitter.com/KYt31GwHSU
#ModelAngelo is changing that, as the bulk of #cryoEM structures can now be built automatically. 🤩
— Sjors Scheres (@SjorsScheres) October 21, 2023
And our new #DynaMight paper is out on @biorxivpreprint! 🥳This is #RELION5's answer to modelling molecular flexibility by the amazing Johannes Schwab. He also shows that model bias can be nasty when modelling molecular flexibility with many parameters.
— Sjors Scheres (@SjorsScheres) October 19, 2023
https://t.co/hvjQb05jl7
This is a numbers game and I would estimate many more computers running 24/7 unnecessarily relentlessly emitting CO2. If we could know what jobs are worth running and which are not that would have been great (like deciding which flights are worth taking) 🤣
— Tamir Gonen (@gonenlab) October 18, 2023
Thoughts and opinions
Never considered the work we do "right wing" …we do basic science and are testing hypotheses…nothing more or less. https://t.co/QuHZSrJpL0
— BryanRoth (@zenbrainest) November 23, 2023
Still can't get over the irony that the best platform for myeloma therapy is an Ikaros degrader (lenalidomide) paired with a molecule that blocks protein degradation (bortezomib). https://t.co/xx89DCPT0A
— Jay Bradner, M.D. (@jaybradner) November 21, 2023
What to do with these relics? pic.twitter.com/WtZ4dBIYKW
— Tamir Gonen (@gonenlab) November 20, 2023
Everything was better in the seventies #CCPEM #3DEM
— Wim Hagen (@WimJHH) November 15, 2023
PSA: #cryoEM folks, don't let your fine motor skills atrophy. I haven't handled a grid in almost 10 years and it showed today. Painfully. pic.twitter.com/E6Zsw40LUq
— David Dranow 🇮🇱 (@GntlmnScientist) October 24, 2023
I hate it when biotechs raise money only when their backs are to the wall $ARQT had many months to raise money when stock was in the teens
— Dan Rosenblum (@sharkbiotech) October 19, 2023
now that its at an all time low they are going to dilute holders by over 30%
"raise when you can, not when you have to"
Smaller protein complexes in the 80kDa range are now routinely solved by #CryoEM meaning a large number of #Kinases in complex with substrates/modulators/activators (like our recent MAP kinase https://t.co/BwBZb8i7Hl) will be solved in the coming years - exciting times! https://t.co/5sNYU0m5pS
— Matthew Bowler (@moncourvoisier) October 18, 2023
Biotech news and drug discovery technologies
We have reached an agreement in principle for Sam Altman to return to OpenAI as CEO with a new initial board of Bret Taylor (Chair), Larry Summers, and Adam D'Angelo.
— OpenAI (@OpenAI) November 22, 2023
We are collaborating to figure out the details. Thank you so much for your patience through this.
Pharmas are changing strategy in response to the IRA by favoring biologics and prioritizing large indications over fast-to-market small indications.
— Alex Harding (@AlexHarding7) November 21, 2023
Biotechs need to catch up.
Read my article for @timmermanreport 👇 https://t.co/eRijMqVrIH
The ADC space is blowing up:
— Andrew Pannu (@andrewpannu) November 21, 2023
• >$125B in partnerships and M&A since 2019, including Pfizer's $43B acquisition of $SGEN and a record $5.5B upfront deal ($MRK / Daiichi) this year
• Hundreds of assets across thousands of trials
• 8 approvals in the last 5 years (13 total)
I… pic.twitter.com/uYf96WljvY
A monumental work by John Ingraham and team @generate_biomed on Chroma✨ for protein design. Congrats!!! 🔥🎉🔥🎉
— Ellen Zhong (@ZhongingAlong) November 15, 2023
So excited to see it out, fully open source and with experimentally validated xtal structures! Perhaps cryo-EM of the giant complexes next?https://t.co/D1cMEqoT6G https://t.co/BwxfllNUm1 pic.twitter.com/Q9mCiBORA8
U.K. approves world's first CRISPR-based medicine, giving greenlight to therapy for sickle cell, thalassemia https://t.co/9KtfeNmHjV
— Adam Feuerstein ✡️ (@adamfeuerstein) November 16, 2023
U.K. regulators beat FDA and EMA by approving the $VRTX $CRSP therapy for sickle cell. via @DrewQJoseph
How competitive recent Biotech M&A deals were?
— Paras Sharma (@paras_biotech) November 4, 2023
**Prometheus had 15 parties in the Data room
Source: Cantor pic.twitter.com/Dfu8b1NNpD
Interesting status update from DeepMind on AlphaFold (just that, no model, paper, or code). All atom version in the works (similar to RFAA). Meaningful gains on small molecules but far from 'solved' (think AF1 vs AF2). Same w/nucleic acids and antibodies. https://t.co/2hEowQ4gxN pic.twitter.com/nVetmAXfnV
— Mohammed AlQuraishi (@MoAlQuraishi) October 31, 2023
#AtlasRetreat2023 @LifeSciVC's Year In Review is sobering. Interesting to see small molecules ("smiracles"?) still dominating deal appetite. pic.twitter.com/pVDpzaE35k
— Jeb Keiper (@JebKeiper) November 3, 2023
Ozemphoria
All of the available preclinical data(and more to come) support #weightloss independent benefits of GLP-1RAs on CVD, inflammation, and metabolic liver disease. Weight loss helps, but it is not the only driver of benefit https://t.co/wBh9z1FfLQ
— Daniel J Drucker (@DanielJDrucker) November 11, 2023
1/
— Jing Liang 🇺🇦 (@AppleHelix) November 11, 2023
Super interesting data on semaglutide in cardiovascular disease.
10% weight loss was enough to show a mortality benefit in LESS THAN 1 year!
The benefit is going to be so much greater as time goes on. Actuaries better redo their models for annuities and pensions https://t.co/zc5NF6LAqz pic.twitter.com/CyVNsMU5sm
Biotech investors... pic.twitter.com/muKgF6Kw0V
— Adam Feuerstein ✡️ (@adamfeuerstein) November 11, 2023
Tirzepatide got a 2nd approval with diff brand name (Zepbound) for obesity. List price is $1,056/mo, same as Mounjaro for diabetes. Same set of doses
— Bruce Booth (@LifeSciVC) November 8, 2023
If list price & dosage forms aren't diff, is need for 2 brands b/c of managing rebates in diabetes (PBMs) & diff insurance mix?
Several lines of evidence in mice suggest that GLP-1RAs may reduce food intake via Trh Arc neurons that inhibit AgRP neurons and decrease feeding in an AgRP neuron-dependent manner #obesity #weightloss https://t.co/3Rh19OTsDL pic.twitter.com/e6rvoJO49a
— Daniel J Drucker (@DanielJDrucker) November 4, 2023
Semaglutide use in PPL with alcohol use disorder. A survey https://t.co/pR4jKUTFW3 pic.twitter.com/ZSFGD9LQ8K
— Daniel J Drucker (@DanielJDrucker) November 2, 2023
"The market has reached a point of near peak hysteria regarding the impact of GLP-1s"
— Bertrand Delsuc (@BertrandBio) October 18, 2023
follow-on of last week's "GLP1s cure X" topic @adar170 @john_bresnahan https://t.co/IXEFcCUQve pic.twitter.com/AvR7Iw4jgK
About MiTeGen
MiTeGen, founded in 2004 by Cornell University Professor Robert Thorne, is a leading provider of innovative technologies for cryo-EM, crystallography, and other techniques used for probing small molecule and biomolecular structure and function. Our mission is to support researchers in achieving the best possible results throughout the entire process, from sample preparation to data collection.
With a strong emphasis on collaboration, we actively work with academic, government, and industrial researchers in over 40 countries to develop and deliver new tools and methods. Our products have gained recognition and trust within the scientific community, as they have been cited in over 4,500 published research articles. By leveraging concepts and technologies from physics and related fields, we tackle practical challenges faced by our friends and collaborators in the life sciences and other disciplines.
Driven by a passion for cryo cooling, we would like to showcase three of our innovative cryo-EM solutions:
Manual Plunge Cooler and Precision Ethane Cryostat:
Our Manual Plunge Cooler and Precision Cryostat are specifically designed to streamline and optimize your cryo-EM sample vitrification workflow. These systems consist of three components that can be obtained individually or as a complete package, ensuring efficient and successful sample preparation.
Cryo-EM Starter Kits:
Our Cryo-EM starter kits are curated to equip your laboratory with all the necessary tools conveniently packaged together. These kits are ideal for labs aiming to perform basic grid and sample preparation for cryo-EM within their own facility, even on a reduced budget. The kit includes components essential for cryo-EM sample preparation, as well as sample storage and transport solutions.
Cryo-EM AutoGrid Cassette Puck:
Our latest addition, the Cryo-EM AutoGrid Cassette Storage and Shipping puck, builds upon the success of our 2nd generation Cryo-EM Puck. This innovative solution allows users to screen samples on a instrument and seamlessly ship the same AutoGrid cassette puck to a collection facility. It also serves as a convenient storage option for facilities, enabling them to store their cassettes in the puck canes designed to fit into cassette loading stations.
These cryo-EM solutions exemplify our dedication to enhancing cryo cooling capabilities and simplifying workflows in the field of cryo-EM. MiTeGen continues to push the boundaries of innovation, enabling researchers to advance their structural biology studies with greater ease and efficiency.
Contact us at MiTeGen today to arrange a no obligation consultation to learn how we can help you with your research.
